PF-4708671

Name: PF-4708671
Brand: Selleck Chemicals
SKU: S2163
Rating: 5 (32 reviews)

For research use only.

Licensed and Manufactured by Pfizer Catalog No.S2163

32 publications

CAS No. 1255517-76-0

PF-4708671 is a cell-permeable inhibitor of p70 ribosomal S6 kinase (S6K1 isoform) with K_i/IC50 of 20 nM/160 nM in cell-free assays, 400-fold greater selectivity for S6K1 than S6K2, and 4- and >20-fold selectivity for S6K1 than MSK1 and RSK1/2, respectively. PF-4708671 induces autophagy. First S6K1-specific inhibitor to be reported.

Selleck's PF-4708671 has been cited by 32 publications

Cell Death Dis, 2021, 12(1):108

PubMed: 33479203 ( click the link to review the publication )

Nat Commun, 2020, 11(1):3200

PubMed: 32581239 ( click the link to review the publication )

Cell Rep, 2020, 31(12):107800

PubMed: 32579927 ( click the link to review the publication )

Oncogene, 2020, 10.1038/s41388-020-01453-2

PubMed: 32917954 ( click the link to review the publication )

Oncogene, 2020, 10.1038/s41388-020-01497-4

PubMed: 33037411 ( click the link to review the publication )

Signal Transduct Target Ther, 2020, 5(1):153

PubMed: 32843616 ( click the link to review the publication )

Life Sci, 2020, 265:118848

PubMed: 33278383 ( click the link to review the publication )

Cell Mol Life Sci, 2020, 10.1007/s00018-020-03617-5

PubMed: 32804243 ( click the link to review the publication )

FASEB J, 2020, 10.1096/fj.202001183R

PubMed: 32686868 ( click the link to review the publication )

Viruses, 2020, 12(10)E1141

PubMed: 33050000 ( click the link to review the publication )

Nat Cell Biol, 2019, 21(6):778-790

PubMed: 31160710 ( click the link to review the publication )

Theranostics, 2019, 9(19):5464-5477

PubMed: 31534497 ( click the link to review the publication )

Oncogene, 2019, 38(35):6270-6282

PubMed: 31316145 ( click the link to review the publication )

Int J Mol Sci, 2019, 20(18)E4424

PubMed: 31505737 ( click the link to review the publication )

Platelets, 2019, 30(2):241-250

PubMed: 29257917 ( click the link to review the publication )

Nutr Metab (Lond), 2018, 10.1186/s12986-018-0268-9

PubMed: 29743930 ( click the link to review the publication )

NPJ Breast Cancer, 2018, 4:36

PubMed: 30456298 ( click the link to review the publication )

Cell Syst, 2017,

PubMed: 28017544 ( click the link to review the publication )

Cell Death Dis, 2017, 8(1):e2553

PubMed: 28079897 ( click the link to review the publication )

Front Immunol, 2017, 7:685

PubMed: 28138329 ( click the link to review the publication )

Clin Exp Allergy, 2017, 47(4):488-498

PubMed: 28000949 ( click the link to review the publication )

Oncotarget, 2016, 7(8):9163-74

PubMed: 26824321 ( click the link to review the publication )

Oncotarget, 2016, 7(32):52239-52254

PubMed: 27409169 ( click the link to review the publication )

Mol Cancer Ther, 2015, 14(3):799-809

PubMed: 25573956 ( click the link to review the publication )
J Immunol, 2015, 195(6):2529-39

PubMed: 26276876 ( click the link to review the publication )

J Biol Chem, 2015, 290(9):5592-605

PubMed: ( click the link to review the publication )

J Biol Chem, 2015, 290(9):5592-605

PubMed: 25561726 ( click the link to review the publication )

Toxicol Lett, 2015, 233(2):102-113

PubMed: 25597859 ( click the link to review the publication )

Cell Immunol, 2015, 298(1-2):9-17

PubMed: 26302934 ( click the link to review the publication )

Cell Signal, 2015, 27(11):2191-200

PubMed: 26210887 ( click the link to review the publication )

PLoS One, 2014, 9(2):e90388

PubMed: 24587347 ( click the link to review the publication )

Oncotarget, 2014, 5(10):3145-58

PubMed: 24762669 ( click the link to review the publication )

Purity & Quality Control

Choose Selective S6 Kinase Inhibitors

Biological Activity

Description

Targets

p70 S6K1 ^[1]
(Cell-free assay)

160 nM

In vitro

PF-4708671 is a piperazinyl-pyrimidine analogue and the first S6K1-specific inhibitor. PF-4708671 does not significantly inhibit the activity of the closely related S6K2 isoform or a number of other AGC kinases (Akt1, Akt2, PKA, PKCα, PKCϵ, PRK2, ROCK2, RSK1, RSK2 or SGK1) . PF-4708671 prevents the S6K1-mediated phosphorylation of S6 protein in response to IGF-1 (insulin-like growth factor 1), while having no effect upon the PMA-induced phosphorylation of substrates of the highly related RSK (p90 ribosomal S6 kinase) and MSK (mitogen- and stress-activated kinase) kinases. PF-4708671 is also found to induce phosphorylation of the T-loop and hydrophobic motif of S6K1, an effect that is dependent upon mTORC1 (mTOR complex 1). PF-4708671 does not affect activity of mTORC1. ^[1]

Cell Data

Cell Lines	Assay Type	Activity Description	PMID
BHT-101	NX3vSnZUT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NFHFcmlKSzVyPUCuPFIxOjRizszN	NG[wdHFUSU6JRWK=
UACC-893	NXeyTYIzT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MV\JR\|UxRTVwMUm4PFYh\|ryP	NWPEcJF4W0GQR1XS
A427	M17Ld2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NH3pe3VKSzVyPUWuO\|I2PjdizszN	Ml[xV2FPT0WU
OCUB-M	MoC3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M13ZV2lEPTB;Nj62OlExOiEQvF2=	Mn\nV2FPT0WU
SW684	M3HodGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NUXxXpZSUUN3ME23MlUzOjZ6IN88US=>	M2G1TXNCVkeHUh?=
SK-LMS-1	NGHEdVlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NITRWYRKSzVyPUmuNFE{ODJizszN	MlqzV2FPT0WU
CP50-MEL-B	MmLwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MmTzTWM2OD17LkOwOFE6KM7:TR?=	NXTydnVVW0GQR1XS
NCI-H1651	NIKzV2dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	Mmj3TWM2OD1zMD6wNlc3KM7:TR?=	M3j5RXNCVkeHUh?=
ABC-1	NIDwRWVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NWDpcWE4UUN3ME2xNE4yODN5IN88US=>	MlvCV2FPT0WU
OE19	MnfMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NHjDcVZKSzVyPUGwMlE4OzNizszN	NYXCNVROW0GQR1XS
DSH1	NFPSS5dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	Mm\VTWM2OD1zMD64PFc6KM7:TR?=	NG\Dd41USU6JRWK=
SW13	MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MXHJR\|UxRTFzLkmzNVkh\|ryP	MnLhV2FPT0WU
MDA-MB-453	MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M3jlb2lEPTB;MUKuNVYxOyEQvF2=	NHPpbmxUSU6JRWK=
647-V	MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M3m0ZmlEPTB;MUKuN\|U5OiEQvF2=	M4HabHNCVkeHUh?=
NCI-H2342	MonOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MY\JR\|UxRTF{LkO5PVUh\|ryP	Mn;DV2FPT0WU
LB2241-RCC	M4O5T2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NEHzR3NKSzVyPUGyMlU4PzlizszN	MmfFV2FPT0WU
UACC-257	MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NGTESWJKSzVyPUGzMlQ1PTNizszN	NUDHRmE3W0GQR1XS
NCI-H661	NGPWTmFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NU\5W2tMUUN3ME2xN{43PDR7IN88US=>	NGfsVmVUSU6JRWK=
FADU	MkPlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NHTPNnpKSzVyPUGzMlY6QTJizszN	NX[zV202W0GQR1XS
A2780	NVTyfItpT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	Mmf6TWM2OD1zMz64NFQyKM7:TR?=	MljYV2FPT0WU
NCI-H1793	M3K2d2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NIK0V\|RKSzVyPUG0MlQxQDVizszN	NFjpXm9USU6JRWK=
TE-8	MljWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NE\lc5JKSzVyPUG1MlM1PjVizszN	M2\DS3NCVkeHUh?=
HGC-27	NXzs[ZpDT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	Mmr0TWM2OD1zNj6xOlQ1KM7:TR?=	NWTqXY5MW0GQR1XS
MMAC-SF	NF7qTXNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NH;0VnpKSzVyPUG3MlM4OjdizszN	M3jyZnNCVkeHUh?=
Calu-6	MmHtS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MlvQTWM2OD1zOD6xOVE{KM7:TR?=	M4LBS3NCVkeHUh?=
HUTU-80	NXi2[5djT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MX3JR\|UxRTF6LkO5OVkh\|ryP	Mk\RV2FPT0WU
SAS	MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NVLrXJA4UUN3ME2xPE43PDV3IN88US=>	NV[wVGo4W0GQR1XS
IST-MES1	NFrxc2FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NIPLT2ZKSzVyPUG4MlY2ODhizszN	NE\zbmpUSU6JRWK=
C3A	MkDNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NWnhem12UUN3ME2xPE44QTF7IN88US=>	NYe3dZlqW0GQR1XS
ES3	NYPOfYVNT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NFzsWmZKSzVyPUG4Mlg{PjRizszN	NGnMfI9USU6JRWK=
HSC-2	M1ntRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MYrJR\|UxRTF7Lk[1OFEh\|ryP	NW\Ob2VsW0GQR1XS
T47D	NF7VRoFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MYXJR\|UxRTJyLkG0PFUh\|ryP	NGTyS4dUSU6JRWK=
EW-7	Ml31S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MnfYTWM2OD1{MD64OVg5KM7:TR?=	MnXHV2FPT0WU
LN-405	NWn5SVFIT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MnO3TWM2OD1{MD64PVY2KM7:TR?=	NGTWcllUSU6JRWK=
U031	M2HicGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MVjJR\|UxRTJzLkS4NFIh\|ryP	NIX0c3FUSU6JRWK=
A549	MmP6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NY[3RZZMUUN3ME2yNU45PDlzIN88US=>	Ml;JV2FPT0WU
RMG-I	MkGyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NUfHRoNnUUN3ME2yNk4zPjZ6IN88US=>	M3rESXNCVkeHUh?=
BT-474	MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NYrONGFGUUN3ME2yNk43PTVzIN88US=>	M1rNcXNCVkeHUh?=
NB69	NHPNUm1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MoGxTWM2OD1{Mz6xOVIh\|ryP	M{[5fHNCVkeHUh?=
NB7	Ml3qS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MkDnTWM2OD1{ND6xPFgh\|ryP	NXPET2NlW0GQR1XS
HCC1569	M{TBSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MVHJR\|UxRTJ2Lk[xNlUh\|ryP	NWHQdFh4W0GQR1XS
MEL-JUSO	NXHSXIlxT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	Mn3sTWM2OD1{ND62PVA5KM7:TR?=	Mk[0V2FPT0WU
MDA-MB-175-VII	NVyxUodiT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NH;keFlKSzVyPUK1MlI2OTdizszN	NGLwb\|ZUSU6JRWK=
HCC1419	NGX5VFJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M3;zdGlEPTB;MkWuOlAxOyEQvF2=	M3TTZXNCVkeHUh?=
Ca9-22	NEK4T5dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M4W2XWlEPTB;MkWuOlQ{OiEQvF2=	NEnTOY1USU6JRWK=
KGN	Mk\HS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MX3JR\|UxRTJ3Lke1OFch\|ryP	NFvFZWlUSU6JRWK=
LB373-MEL-D	NFnyXmJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M3TObmlEPTB;Mk[uNVk{QCEQvF2=	NYr4[Hk5W0GQR1XS
NCI-H1755	M4HsRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MYrJR\|UxRTJ4Lki4OFEh\|ryP	NYnUVJltW0GQR1XS
D-423MG	M4ruXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NIrxSZpKSzVyPUK3MlA4OTVizszN	M{PtVXNCVkeHUh?=
DK-MG	NEHwdYlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M4[4TGlEPTB;MkiuO\|g1PiEQvF2=	NX\zXWpMW0GQR1XS
NCI-H1623	MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NEjrNIJKSzVyPUK4Mlg{PDJizszN	NY[zV3M6W0GQR1XS
KU-19-19	MmfjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M3jZUWlEPTB;MkiuPVk2KM7:TR?=	NELaXVBUSU6JRWK=
C-33-A	M2fpN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M3XkO2lEPTB;MkmuNlE6QCEQvF2=	M1PiZnNCVkeHUh?=
SCC-4	M3fEZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M{\x[2lEPTB;M{CuN\|M2PCEQvF2=	NEjFWFRUSU6JRWK=
MG-63	NXOwN\|l2T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M2jScWlEPTB;M{CuOVk6PCEQvF2=	NYnpOYc6W0GQR1XS
LNCaP-Clone-FGC	NV3yNmtIT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NGHUWYpKSzVyPUOxMlQ6OjFizszN	MmTBV2FPT0WU
CAPAN-1	NVi4XoxmT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MVHJR\|UxRTNzLkWyPFYh\|ryP	M3L5WXNCVkeHUh?=
GI-ME-N	MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M4D1cmlEPTB;M{GuOVM2OyEQvF2=	MkThV2FPT0WU
RERF-LC-MS	NUfCOopxT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MmjYTWM2OD1\|Mj62O\|Q4KM7:TR?=	NInDUJVUSU6JRWK=
KLE	MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MofJTWM2OD1\|Mz60N\|M1KM7:TR?=	MlTGV2FPT0WU
KNS-81-FD	M{PoSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M2LpfmlEPTB;M{OuOVAxQCEQvF2=	NGTR[I5USU6JRWK=
DOK	MnvZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MXvJR\|UxRTN2Lk[2NVIh\|ryP	NHnCUHRUSU6JRWK=
ACHN	Mk\1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MV3JR\|UxRTN3LkG1PFgh\|ryP	MlzUV2FPT0WU
KYSE-520	NIHxfWRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NXP5NJpJUUN3ME2zOU4zOzZzIN88US=>	NG\CbZBUSU6JRWK=
SBC-5	M3vrU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NHzie3VKSzVyPUO1MlUyOTZizszN	MkDUV2FPT0WU
NCI-H28	NUHjVHhCT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MXTJR\|UxRTN3Lk[2PVUh\|ryP	M1LESXNCVkeHUh?=
ES7	NIG3c4pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NXP3UJF7UUN3ME2zOk4zOjR7IN88US=>	NInxZVFUSU6JRWK=
A172	NVL5R3N[T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NYjjVI17UUN3ME2zOk41OTh5IN88US=>	NWTPWVBvW0GQR1XS
UM-UC-3	M4e3U2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MnjGTWM2OD1\|Nz64O\|Q3KM7:TR?=	MnHBV2FPT0WU
LXF-289	MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MlHoTWM2OD1\|OD6wNFQ4KM7:TR?=	MmXBV2FPT0WU
KP-4	NU\VbJdnT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M4j3e2lEPTB;M{iuOFc{QSEQvF2=	MVnTRW5ITVJ?
TE-1	MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MkjBTWM2OD1\|OT62OVg6KM7:TR?=	Ml\HV2FPT0WU
G-402	MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NGXTWY5KSzVyPUSwMlA3OSEQvF2=	NW\3T3d1W0GQR1XS
786-0	M4\lU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MXzJR\|UxRTRyLkmwPVYh\|ryP	MkmxV2FPT0WU
K5	NFXIRlFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NXHvTmNDUUN3ME20NU4{Pjh4IN88US=>	M{HESHNCVkeHUh?=
SK-N-DZ	M2mxVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	Mlf6TWM2OD12MT6zPFI{KM7:TR?=	M37NWXNCVkeHUh?=
OVCAR-4	NVTTWXBIT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	Mli0TWM2OD12MT63OVY5KM7:TR?=	M1rlfHNCVkeHUh?=
T84	NIHGb\|NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NI\CNoFKSzVyPUSyMlEzPjNizszN	NInybZFUSU6JRWK=
GCIY	NU\nT5E1T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NFvEWWJKSzVyPUSzMlA5ODNizszN	Mm\SV2FPT0WU
BB49-HNC	Mn\ES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MYrJR\|UxRTR\|LkOzOFgh\|ryP	MkjhV2FPT0WU
SNU-C2B	NVzGXmkzT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NInXZYtKSzVyPUSzMlY1OzZizszN	M{L2OnNCVkeHUh?=
TE-6	NVj3XlRET3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NUnmSWdsUUN3ME20N{45QDl2IN88US=>	M2GxS3NCVkeHUh?=
23132-87	NXjtbZVoT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	Mm[5TWM2OD12ND6yPVc5KM7:TR?=	M2PhOXNCVkeHUh?=
DMS-53	Mn;oS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NV\pSXhvUUN3ME20OE4{Ozh2IN88US=>	MX\TRW5ITVJ?
ONS-76	M4XYZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M1jjS2lEPTB;NESuO\|Y3OSEQvF2=	MkLLV2FPT0WU
DMS-273	M3T2XGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M1j0cWlEPTB;NESuPVQ{KM7:TR?=	M4\hb3NCVkeHUh?=
COLO-824	MlnrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MWjJR\|UxRTR3Lki3O\|Uh\|ryP	NVXPV2VUW0GQR1XS
DMS-114	M3K1Rmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M4LC[GlEPTB;NEWuPFkzPyEQvF2=	MnPQV2FPT0WU
YKG-1	MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MmTsTWM2OD12Nj6wN\|U2KM7:TR?=	NYj3XZdKW0GQR1XS
RH-18	NXO1dJdoT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NVK1NodqUUN3ME20Ok4{PzN\|IN88US=>	MWDTRW5ITVJ?
NCI-H1355	NEHLdIpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NV7ZbIpFUUN3ME20Ok43OThizszN	NFvSRoxUSU6JRWK=
NCI-H2170	M{HieWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MX;JR\|UxRTR5Lke1PFQh\|ryP	NEH1V2FUSU6JRWK=
OC-314	NWm0WnNTT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MmO0TWM2OD12Nz64OFc5KM7:TR?=	NGfh[JVUSU6JRWK=
NCI-H2030	NGT3OY5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NFrwbY5KSzVyPUS3Mlg6ODZizszN	M37ZcHNCVkeHUh?=
22RV1	M4jXUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MnjZTWM2OD12Nz65NFE2KM7:TR?=	NFvzRoZUSU6JRWK=
G-401	NVXifJNMT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MmL5TWM2OD12OD60OFE2KM7:TR?=	MWrTRW5ITVJ?
YAPC	MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NX3ncpJGUUN3ME20PU45ODd\|IN88US=>	MoO5V2FPT0WU
SW1573	MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M3TOdGlEPTB;NUCuNlQ{PSEQvF2=	NHX0N\|RUSU6JRWK=
COLO-792	M3ruRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NULwdmMzUUN3ME21NE43OjN5IN88US=>	MlvwV2FPT0WU
KNS-62	M{mxfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MlTpTWM2OD13MD63OVA5KM7:TR?=	NEDjOopUSU6JRWK=
NB5	MlW5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MYTJR\|UxRTVzLkS1NFkh\|ryP	MUfTRW5ITVJ?
CP66-MEL	M1XZWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NX30W3loUUN3ME21NU43PDB6IN88US=>	Ml:1V2FPT0WU
CaR-1	MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NYr4W5JKUUN3ME21Nk4xPjB4IN88US=>	NYrmfFh7W0GQR1XS
CAL-54	M2\YbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NXXCRWhRUUN3ME21Nk4yOTB{IN88US=>	MXTTRW5ITVJ?
8305C	NV3ie2E3T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MlHaTWM2OD13Mj6zNVUh\|ryP	NHv2b5BUSU6JRWK=
Calu-3	NFqyTZFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M3nrTWlEPTB;NUKuN\|c{OyEQvF2=	M{nx[XNCVkeHUh?=
AU565	NHjtO4dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NELOVppKSzVyPUWyMlU2ODlizszN	NFnkVlJUSU6JRWK=
CW-2	MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M1XwWWlEPTB;NUKuPFY2PCEQvF2=	M2DNSHNCVkeHUh?=
BEN	NIHzdpRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NH63coNKSzVyPUWzMlc5PjJizszN	M3S4[nNCVkeHUh?=
NCI-H1975	NVjSR2NRT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NUHhPVFKUUN3ME21N{45QTZ4IN88US=>	M2PBd3NCVkeHUh?=
HCT-116	NX\vO3dxT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MlO2TWM2OD13ND6wN\|I4KM7:TR?=	MVPTRW5ITVJ?
SH-4	M3HtZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MkjtTWM2OD13ND6xN\|gh\|ryP	M3XPdHNCVkeHUh?=
NCI-H1693	Ml[zS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NIfTPHlKSzVyPUW0MlIyODNizszN	MofJV2FPT0WU
BPH-1	NW\1d3VCT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NFPCNJZKSzVyPUW1MlI5QTJizszN	MWLTRW5ITVJ?
CAMA-1	NYjPco56T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NF20VFVKSzVyPUW1MlgyOTZizszN	MXzTRW5ITVJ?
A388	MkjMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NWWwTJNOUUN3ME21Ok4xQTh3IN88US=>	MVvTRW5ITVJ?
C2BBe1	MlrOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MYnJR\|UxRTV4LkK2N\|Qh\|ryP	M{PXUHNCVkeHUh?=
GAMG	NVOyU4NZT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NYTaTWFnUUN3ME21Ok42QTV3IN88US=>	MW\TRW5ITVJ?
MKN28	NGnqbXNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NVnGcHBSUUN3ME21Ok45ODF\|IN88US=>	MWDTRW5ITVJ?
VA-ES-BJ	MkPZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MUDJR\|UxRTV4Lki3OFUh\|ryP	MVTTRW5ITVJ?
HuCCT1	NVe4W\|d5T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NVXKcWh4UUN3ME21O{4xPDl{IN88US=>	MWjTRW5ITVJ?
BFTC-905	M{jBSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MnHDTWM2OD13Nz6yPFk5KM7:TR?=	Mki4V2FPT0WU
LS-123	NHnyN5lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M3zSU2lEPTB;NUeuOVY3QCEQvF2=	MU\TRW5ITVJ?
LB996-RCC	NHfZUllIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NU\vc3E{UUN3ME21PE4xOjh5IN88US=>	MmnRV2FPT0WU
NCI-H1048	M4TrVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NH2xOmFKSzVyPUW4MlIyQDhizszN	NI\MZYhUSU6JRWK=
COR-L105	MoLGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M3TuS2lEPTB;NUiuO\|M{PyEQvF2=	NFLrVppUSU6JRWK=
OVCAR-8	MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M3jtU2lEPTB;NUmuNVcyPiEQvF2=	NGXIR3FUSU6JRWK=
SK-N-FI	NX\6OWdYT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MnjyTWM2OD13OT6zNlA4KM7:TR?=	NVOzeIw6W0GQR1XS
MES-SA	M1nGOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NVLu[XJLUUN3ME21PU41PTB7IN88US=>	NFe2[5RUSU6JRWK=
SCC-9	MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NGn5TWhKSzVyPUW5MlQ4PTNizszN	NULxTIhZW0GQR1XS
EFO-27	MojIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M3noUGlEPTB;NUmuPVQ{KM7:TR?=	NFzseHNUSU6JRWK=
GT3TKB	M{XBTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MmDOTWM2OD14MD62NFQ5KM7:TR?=	NEC1bo5USU6JRWK=
HCC38	NXTWTnZjT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MXjJR\|UxRTZzLkSzO\|kh\|ryP	M4r1PHNCVkeHUh?=
MLMA	NIHXN5hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MYDJR\|UxRTZzLk[xOlMh\|ryP	NUPOOFVFW0GQR1XS
D-566MG	NEK5OWdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MlT2TWM2OD14Mz61NlI1KM7:TR?=	NX;ReFROW0GQR1XS
SF295	M3TyRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MV\JR\|UxRTZ\|Lk[2OVUh\|ryP	MWjTRW5ITVJ?
ES4	NV;ZPYRiT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NHrqe\|BKSzVyPU[0MlQ4OTlizszN	M3XxR3NCVkeHUh?=
CAKI-1	MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NGrLRWFKSzVyPU[0MlU4OjFizszN	MlS0V2FPT0WU
OAW-28	MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MX3JR\|UxRTZ2Lkm2OFch\|ryP	NXP2[4FsW0GQR1XS
NCI-H460	NHjpcHZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NU\rb2FuUUN3ME22OU4xQDl5IN88US=>	MV3TRW5ITVJ?
JAR	NXTiTlhwT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NVPTV3NHUUN3ME22OU42PTF4IN88US=>	MoDhV2FPT0WU
SNU-449	MkT1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NWXkNIpNUUN3ME22OU44PjF4IN88US=>	MWrTRW5ITVJ?
D-392MG	MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MkHlTWM2OD14NT65OFM1KM7:TR?=	MWLTRW5ITVJ?
EW-22	MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NYrYfXlzUUN3ME22Ok4{QTVizszN	MmfTV2FPT0WU
GCT	MnzPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M2C2b2lEPTB;NkeuNFQ1OyEQvF2=	NXriZ45SW0GQR1XS
NOS-1	M{PRbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NFLQZWhKSzVyPU[3MlY5PjdizszN	M{jZOHNCVkeHUh?=
RH-1	MmO4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MUnJR\|UxRTZ6LkW1OVkh\|ryP	M1nX[XNCVkeHUh?=
HuH-7	NEf1OmFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MkCzTWM2OD14OT6xNFAzKM7:TR?=	MVHTRW5ITVJ?
NUGC-3	NV;Zc4JLT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MXHJR\|UxRTdyLkm2OFQh\|ryP	M3vlfXNCVkeHUh?=
IST-SL1	MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MYrJR\|UxRTdzLkKzNlQh\|ryP	NHLTZ3FUSU6JRWK=
SHP-77	NXXweJEzT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MWjJR\|UxRTd{LkGxPUDPxE1?	M2DQfHNCVkeHUh?=
SW1116	NXvyTpdJT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MlOyTWM2OD15Mj6xOFA4KM7:TR?=	NWq1N5p{W0GQR1XS
LK-2	MmfWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MX;JR\|UxRTd{Lki2NVIh\|ryP	M3Ho[nNCVkeHUh?=
U-2-OS	NXfmbYlrT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MYrJR\|UxRTd\|LkG4Nlgh\|ryP	MYLTRW5ITVJ?
KYSE-150	NIjST5JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M3PI[2lEPTB;N{OuOlEyQCEQvF2=	Mnr2V2FPT0WU
U251	MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NXXzdHlnUUN3ME23N{45OTZ6IN88US=>	MWDTRW5ITVJ?
HT-1080	MnnzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MYHJR\|UxRTd2LkK1O\|Qh\|ryP	NGDHdpRUSU6JRWK=
NCI-H1437	M1i1cWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NWXISYR3UUN3ME23OE43OzJ4IN88US=>	NXm0NHBqW0GQR1XS
HPAF-II	M{HqS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MWPJR\|UxRTd2Lk[0NVUh\|ryP	MWjTRW5ITVJ?
Becker	NGrWVpZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	Mn;tTWM2OD15NT6xNVA2KM7:TR?=	MoLsV2FPT0WU
PANC-10-05	MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NI[2c\|hKSzVyPUe1MlI5PjVizszN	MmPMV2FPT0WU
TYK-nu	NXPNSWhPT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MYLJR\|UxRTd3LkOxNFIh\|ryP	NXXlXod2W0GQR1XS
SKG-IIIa	M3SwT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NV\XVYdDUUN3ME23OU4{OzRzIN88US=>	NIjKVJdUSU6JRWK=
NCI-H1993	Mn;YS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M3;mRWlEPTB;N{WuO\|M6PyEQvF2=	NVO3Z41wW0GQR1XS
S-117	NIDWZnFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M1jU[GlEPTB;N{WuO\|U2KM7:TR?=	NF\q[lBUSU6JRWK=
HuO9	M1PHTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NInOPXlKSzVyPUe2MlAxPDhizszN	MnziV2FPT0WU
CAL-51	Mo[2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NFO3dGFKSzVyPUe2MlExODZizszN	Mn3IV2FPT0WU
BT-20	Mk\oS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NUPvVnV3UUN3ME23Ok4zOTZ6IN88US=>	Ml\PV2FPT0WU
LB831-BLC	Mme2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NE\2PYtKSzVyPUe2MlMzOTdizszN	M2X0PHNCVkeHUh?=
LB1047-RCC	M3;0R2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M3S3dWlEPTB;N{[uO\|YyQSEQvF2=	MkfvV2FPT0WU
ES8	MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MlXhTWM2OD15OD6wNFc{KM7:TR?=	MWDTRW5ITVJ?
UMC-11	MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NXnY[IYxUUN3ME23PE4xQDh2IN88US=>	Ml\nV2FPT0WU
NCI-H226	M3zEW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NU\XSZhxUUN3ME23PE4yOzF3IN88US=>	NVPEV5U2W0GQR1XS
IGROV-1	M3HyUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M{fU[2lEPTB;N{iuOVU2KM7:TR?=	MkLEV2FPT0WU
BHY	NEXZNolIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MmrjTWM2OD15OT61PVYh\|ryP	MkTwV2FPT0WU
MKN45	NV;KWWhGT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MkLSTWM2OD16MD6zNVc1KM7:TR?=	M3n0U3NCVkeHUh?=
IA-LM	MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M3zldWlEPTB;OECuN\|UyOSEQvF2=	M2TiOHNCVkeHUh?=
WM-115	NGfxe3JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NHLNXpZKSzVyPUixMlQyOTRizszN	NVvZepFYW0GQR1XS
VMRC-RCZ	MlrCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	Ml\6TWM2OD16MT60OFI2KM7:TR?=	M2TZW3NCVkeHUh?=
NCI-H2291	MoHCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NVfxNIQ6UUN3ME24NU43QDR{IN88US=>	MXPTRW5ITVJ?
MCF7	MkLQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MVLJR\|UxRTh\|LkK4PVch\|ryP	NVfqbGF6W0GQR1XS
639-V	NYXPeYUxT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M2W1UmlEPTB;OESuOlEzQSEQvF2=	NXPtZ5MzW0GQR1XS
RT4	MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NYCxclBkUUN3ME24OU4zPDB\|IN88US=>	MnHZV2FPT0WU
NCI-H2405	Mn3rS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NVzaOZB3UUN3ME24OU4zQTl5IN88US=>	NWf3N5ZDW0GQR1XS
CAL-33	MlXhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NEnneXRKSzVyPUi1MlY{OTVizszN	M1n6eXNCVkeHUh?=
BT-549	M1HrS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MlHDTWM2OD16NT65N\|gzKM7:TR?=	NF7HR\|JUSU6JRWK=
HT-1197	NUT6VGJ3T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NXnHOYw5UUN3ME24PE4yODd5IN88US=>	M1fQO3NCVkeHUh?=
G-361	MoXoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NXv2e5pUUUN3ME24PE4yPDd2IN88US=>	M4DRNnNCVkeHUh?=
LS-411N	MnTNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MlzDTWM2OD16OT6zN\|g5KM7:TR?=	MULTRW5ITVJ?
HT-144	NXzvNoNCT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M3\nXWlEPTB;OEmuOVk6OiEQvF2=	NUfkOWNiW0GQR1XS
DJM-1	MmfkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MVrJR\|UxRTh7Lki4OFUh\|ryP	MVnTRW5ITVJ?
CAL-12T	NXvDTnN3T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NFTuVohKSzVyPUmwMlc5QTVizszN	M2\UcnNCVkeHUh?=
MKN7	NEPkb3ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MmDRTWM2OD17MT6zOVUyKM7:TR?=	Mmf0V2FPT0WU
HuP-T3	NEXWfI9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NWHmWJFFUUN3ME25Ok4yODB2IN88US=>	NEm5XohUSU6JRWK=
SK-MG-1	MoDtS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MX\JR\|UxRTl4LkGzOFgh\|ryP	MmDIV2FPT0WU
NCI-H2347	NH;FUoRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NXy1fHUzUUN3ME25PE4yODR{IN88US=>	MojPV2FPT0WU
SW872	NUfOTHMzT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NHrqNHZKSzVyPUGwNE41PTZizszN	M3v6R3NCVkeHUh?=
COLO-829	MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M1rPWWlEPTB;MUCwMlU2OyEQvF2=	M1n4ZXNCVkeHUh?=
MC-IXC	MornS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MVLJR\|UxRTFyMD62NVUh\|ryP	MnniV2FPT0WU

... Click to View More Cell Line Experimental Data

Assay

Methods	Test Index	PMID
Western blot	pS6 / S6 / pS6K / S6K1 / pAKT / AKT ; PubMed: 28626016 J Neurosci Western blot of cell lysates from neurons treated with PF-4708671, rapamycin, and Torin-2, individually or in combination for the indicated times. p-mTOR / mTOR / p-p70S6K / p70S6K ; PubMed: 30423811 Int J Mol Sci As determined using Western blotting, the phospho-p70S6K (p-p70S6K) inhibitor (PF-4708671) reduced the expression of phospho-mTOR (p-mTOR) and p-p70S6K in SCC-4 and SCC-25 cells. SCC-4 and SCC-25 cells were not treated as negative control (NC) or treated with 20 µM PF-4708671 for 6 h (6 h), 12 h (12 h), 18 h (18 h), 1 day (1 d), 2 days (2 d), and 3 days (3 d). Western blot analysis was performed to examine the expression levels of p-mTOR, mTOR, p-p70S6K, p70S6K, and β-actin.	28626016 30423811
Growth inhibition assay	Cell viability; PubMed: 30423811 Int J Mol Sci Inhibitory effects of various doses (0.5, 1, 2, 5, 10, 20, and 40 µM) of PF-4708671 on SCC-4 (B) and SCC-25 (C) cells were assessed using MTT assay after 72 h of treatment. Data presented are the mean and standard error of the mean of three independent experiments. * p < 0.05, p < 0.01, and * p < 0.001 indicate the statistical significance of differences between cells with and without treatment. t (red and * for SCC-4 and blue , * and *** for SCC-25).	30423811

Protocol

References

[1] Pearce LR, et al. Biochem J, 2010, 431(2), 245-255.

Solubility (25°C)

In vitro	DMSO	30 mg/mL (76.84 mM)
	Ethanol	8 mg/mL (20.49 mM)
	Water	Insoluble
In vivo	Add solvents to the product individually and in order(Data is from Selleck tests instead of citations): 30% PEG400+0.5% Tween80+5% propylene glycol For best results, use promptly after mixing.	30 mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information Download PF-4708671 SDF

Molecular Weight	390.41
Formula	C₁₉H₂₁F₃N₆
CAS No.	1255517-76-0
Storage	3 years-20°C powder 2 years-80°C in solvent
Synonyms	N/A
Smiles	CCC1=CN=CN=C1N2CCN(CC2)CC3=NC4=C(N3)C=C(C=C4)C(F)(F)F

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

Dosage

mg/kg

Average weight of animals

Dosing volume per animal

Number of animals

Step 2: Enter the in vivo formulation (Different batches have different solubility ratios, please contact Selleck to provide you with the correct ratio)

% DMSO+ % + % Tween 80+ % ddH₂O

Calculate Reset

Calculation results:

Working concentration： mg/ml；

Method for preparing DMSO master liquid: ： mg drug pre-dissolved in μL DMSO (Master liquid concentration mg/mL， Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation：Take μL DMSO master liquid, next addμL PEG300， mix and clarify, next addμL Tween 80，mix and clarify, next add μL ddH₂O，mix and clarify.

Note：1.Please make sure the liquid is clear before adding the next solvent.
2.Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.

Bio Calculators

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration _(start) x Volume _(start) = Concentration _(final) x Volume _(final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

Serial Dilutions
Concertration (start):
Dilution-folds:

Computed Result

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

Frequently Asked Questions

Question 1:
Whether the in vivo formula "30% PEG400+0.5% Tween80+5% Propylene glycol" for S2163 is suitable for i.p. or not?
Answer:
The formula "30% PEG400+0.5% Tween80+5% Propylene glycol" on our website is an oral one. It is a suspension.

S6 Kinase Signaling Pathway Map

Related S6 Kinase Products

LY2584702 ^New

LY2584702 is a selective, ATP-competitive p70S6K inhibitor with IC50 of 4 nM. Phase 1.
LY2584702 Tosylate ^New

LY2584702 Tosylate is a selective, ATP-competitive p70S6K inhibitor with IC50 of 4 nM. Phase 1.
CHIR-99021 (CT99021) ^New

CHIR-99021 (CT99021) is a GSK-3α and GSK-3β inhibitor with IC50 of 10 nM and 6.7 nM, respectively. CHIR99201 does not exhibit cross-reactivity against cyclin-dependent kinases (CDKs) and shows a 350-fold selectivity toward GSK-3β compared to CDKs. CHIR99021 functions as a Wnt/β-catenin activator and induces autophagy.
BI-D1870

BI-D1870 is an ATP-competitive inhibitor of S6 ribosome for RSK1/2/3/4 with IC50 of 31 nM/24 nM/18 nM/15 nM in cell-free assays, respectively; 10- to 100-fold selectivity for RSK than MST2, GSK-3β, MARK3, CK1 and Aurora B. BI-D1870 exhibits anticancer attributes including the generation of reactive oxygen species (ROS) and increases in endoplasmic reticulum (ER) stress and autophagy.
Rapamycin (Sirolimus)

Rapamycin (Sirolimus, AY 22989, NSC-2260804) is a specific mTOR inhibitor with IC50 of ~0.1 nM HEK293 cells.
MK-2206 2HCl

MK-2206 2HCl is a highly selective inhibitor of Akt1/2/3 with IC50 of 8 nM/12 nM/65 nM in cell-free assays, respectively; no inhibitory activities against 250 other protein kinases observed. MK-2206 2HCl induces autophagy and apoptosis in cancer cells. Phase 2.

Features:The first allosteric small molecule inhibitor of Akt to enter clinical development.
CHIR-99021 (CT99021) HCl

CHIR-99021 (CT99021) HCl is hydrochloride of CHIR-99021, which is a GSK-3α/β inhibitor with IC50 of 10 nM/6.7 nM; CHIR-99021 shows greater than 500-fold selectivity for GSK-3 versus its closest homologs Cdc2 and ERK2. CHIR-99021 is a potent pharmacological activators of the Wnt/beta-catenin signaling pathway. CHIR-99021 significantly rescues light-induced autophagy and augments GR, RORα and autophagy-related proteins.
LY294002

LY294002 (SF 1101, NSC 697286) is the first synthetic molecule known to inhibit PI3Kα/δ/β with IC50 of 0.5 μM/0.57 μM/0.97 μM, respectively; more stable in solution than Wortmannin, and also blocks autophagosome formation. It not only binds to class I PI3Ks and other PI3K-related kinases, but also to novel targets seemingly unrelated to the PI3K family. LY294002 also inhibits CK2 with IC50 of 98 nM. LY294002 is a non-specific DNA-PKcs inhibitor and activates autophagy and apoptosis.
3-Methyladenine (3-MA)

3-Methyladenine (3-MA, NSC 66389) is a selective PI3K inhibitor for Vps34 and PI3Kγ with IC50 of 25 μM and 60 μM in HeLa cells; blocks class I PI3K consistently, whereas suppression of class III PI3K is transient, and also blocks autophagosome formation. 3-Methyladenine (3-MA) is successfully used to suppress mitophagy. Solutions of 3-MA are best fresh-prepared by heating.
Everolimus (RAD001)

Everolimus (RAD001) is an mTOR inhibitor of FKBP12 with IC50 of 1.6-2.4 nM in a cell-free assay. Everolimus induces cell apoptosis and autophagy and inhibits tumor cells proliferation.

Choose Your Country or Region

By Signaling Pathways

By product type

PF-4708671